| 2.78 0 (0%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.63 | 1-year : | 4.06 |
| Resists | First : | 3.11 | Second : | 3.48 |
| Pivot price | 2.85  |
|||
| Supports | First : | 2.52 | Second : | 2.1 |
| MAs | MA(5) : | 2.72  |
MA(20) : | 2.96 |
| MA(100) : | 3.03 |
MA(250) : | 2.07 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 27.1 |
D(3) : | 22.3 |
| RSI | RSI(14): 39.9 | |||
| 52-week | High : | 4.36 | Low : | 0.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MREO ] has closed above bottom band by 41.9%. Bollinger Bands are 11.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.89 - 2.9 | 2.9 - 2.91 |
| Low: | 2.73 - 2.74 | 2.74 - 2.76 |
| Close: | 2.76 - 2.78 | 2.78 - 2.8 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Mon, 22 Apr 2024
Mereo BioPharma Group plc (NASDAQ:MREO) to Post FY2024 Earnings of ($0.05) Per Share, Cantor Fitzgerald ... - MarketBeat
Wed, 10 Apr 2024
Mereo BioPharma Group (NASDAQ:MREO) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Wed, 10 Apr 2024
Mereo's Pipeline Promise Vs. Valuation And Market Realities (NASDAQ:MREO) - Seeking Alpha
Wed, 03 Apr 2024
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference - Investing.com South Africa
Thu, 28 Mar 2024
Mereo Biopharma Group Plc ADR Up 9.66% To $3.29 After Earnings - InvestorsObserver
Wed, 27 Mar 2024
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 140 (M) |
| Held by Insiders | 3.125e+008 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 2,230 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.657e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -294.7 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 576.5 % |
| Return on Equity (ttm) | -23.6 % |
| Qtrly Rev. Growth | 1e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -74.12 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 6.02 |
| Dividend | 0 |
| Forward Dividend | 2.33e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|